Document:

EX-4.6

 Exhibit 4.6 

THIS CONVERTIBLE PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN
COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER SATISFACTORY TO THE COMPANY (AS DEFINED BELOW) THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT. 

CONVERTIBLE PROMISSORY NOTE 

November 12, 2013 
 Louisville,
Colorado 
 For value received, GLOBEIMMUNE, INC., a Delaware corporation (the
“Company”), unconditionally promises to pay to Cooley LLP or its assigns (the “Holder”) the principal sum of $391,730.00 with interest on the outstanding principal amount at the rate of 8% per
annum (subject to adjustment as set forth below), or the maximum rate permissible by law, whichever is less, simple interest, and calculated on the basis of a 360-day year for the actual number of days elapsed. Interest shall commence with the date
hereof and shall continue on the outstanding principal balance hereof until paid in full. The principal balance of this Note, together with the accrued interest thereon shall be due and payable on the dates and in the manner set forth below. 

1. Maturity; Interest; Payments; Prepayment; Waiver of Presentment. 

(a) Maturity Date. At any time on or after November 12, 2016 (the “Maturity Date”), if this Note has not
been paid in full or converted in accordance with the terms of Section 2(a) or Section 2(b) below, the Note, including any accrued interest, shall convert in accordance with Section 2(c) below. 

(b) Payments. All payments of principal and interest shall be in lawful money of the United States of America and shall be payable at
the office of the Holder, unless another place of payment shall be specified in writing by the Holder. All payments shall be applied first to any fees or expenses due to the Holder, then to accrued interest, including any interest that accrues after
the commencement of a proceeding by or against the Company under Title 11 of the United States Code, and thereafter to the outstanding principal balance hereof. If any payments on this Note become due on a Saturday, Sunday, or a public holiday under
the laws of the State of Colorado, such payment shall be made on the next succeeding business day and such extension of time shall be included in computing interest in connection with such payment. 

(c) Prepayment. This Note may be prepaid in whole or in part at any time. 

(d) Waiver. The Company hereby waives demand, notice, presentment, protest and notice of dishonor. 

  
 1. 

 2. Conversion.  

(a) Qualified Financing. In the event that (i) the Company issues and sells shares of its Preferred Stock in a private placement
(the “Preferred Stock”), or Common Stock in a Registered Public Offering, to investors (the “Investors”) in a bona fide arm’s-length transaction for aggregate consideration (including
conversion of any outstanding indebtedness) of at least $5,000,000 (the “Qualified Financing”) and (ii) this Note has not been paid in full, then the entire outstanding principal balance and all unpaid accrued interest
of this Note shall automatically convert in whole without any further action by the Holder into shares of the equity security inssued in such financing at a conversion price equal to eighty percent (80%) of the price per share paid by the
Investors purchasing the Preferred Stock (such price per share paid by the investors without such discount, the “Preferred Stock Conversion Price”) or shares of Common Stock in a Registered Public Offering (such price per
share paid by the investors without such discount, the “Common Stock Conversion Price”) on the same terms and conditions as given to the Investors. If the Company completes a financing which would otherwise be a Qualified
Financing but does not meet the minimum dollar amount, the Holder shall have the option to convert this note into such financing as if it were a Qualified Financing. 

(b) Corporate Transaction. In the event that (i) the Company enters into an agreement pertaining to (A) a sale, lease or
other disposition of all or substantially all of its assets or (B) a consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, in which the stockholders of the
Company immediately prior to such consolidation, merger or reorganization own less than 50% of the voting power of the surviving entity immediately after such consolidation, merger or reorganization (each such event being referred to herein as a
“Corporate Transaction”), and (ii) this Note has not been paid in full or converted in accordance with the terms of Section 2(a) above, then the Holder may, at its sole discretion, immediately prior to the closing
of such Corporate Transaction, convert the outstanding principal balance and all unpaid accrued interest of this Note into the number of shares of Series E Preferred Stock of the Company equal to (i) the outstanding principal balance and all
unpaid accrued interest of this Note, divided by (ii) eighty percent (80%) of the original issue price of the Series E Preferred Stock (as adjusted for stock splits, stock dividends, recapitalizations, combinations or the like) (such
original issue price without such discount, the “Series E Conversion Price”) on the same terms and conditions as given to the investors in the Series E Preferred Stock. 

(c) Automatic Conversion. In the event that (i) the Company has not closed a Qualified Financing or a Corporate Transaction prior
to the Maturity Date, (ii) this Note has not been paid in full or converted in accordance with the terms of
 Sections 2(a) or 2(b) above, and (iii) no Event of Default (as defined below) shall have occurred and be continuing other
than any Event of Default that has been waived in writing by the Holder, then the entire outstanding principal balance and all unpaid accrued interest of this Note shall automatically convert in whole without any further action by the Holder into
the number of shares of Series E Preferred Stock of the Company equal to (i) the outstanding principal balance and all unpaid accrued interest of this Note, divided by (ii) eighty-percent (80%) of a price per share based on a
valuation completed by a independent, third party valuation firm and using methods mutually agreeable to the Company and Holder (such price, the “Adjusted Series E Price”) on the same terms and conditions as given to the
investors in the Series E Preferred Stock other than the price per share. 

  
 2. 

 (d) Conversion Procedures. Upon conversion of this Note pursuant to Section 2(a),
Section 2(b) or Section 2(c) above, the Holder shall surrender this Note, duly endorsed, at the principal office of the Company, and the Company shall, at its expense, upon receipt of this Note, duly endorsed, promptly deliver or cause to
be delivered to the Holder a certificate or certificates (bearing such legends as may be required) representing that number of fully paid and non-assessable shares of the applicable series of the Company’s Preferred Stock into which this Note
may be converted, and any other securities or property to which the Holder may be entitled to receive upon conversion of this Note, including a check payable to the Holder for fractional shares as described in Section 2(e) below. The conversion
of this Note shall be deemed to have been made (i) on the date of the closing of the Qualified Financing pursuant to Section 2(a) above, (ii) on the date the Holder notifies the Company of its election to convert this Note pursuant to
Section 2(b) above or (iii) as described in Section 2(c) above, as applicable, and the Holder shall be treated for all purposes as the record holder of such shares of Preferred Stock, Common Stock or Series E Preferred Stock, as the
case may be, as of such date. 
 (e) Fractional Shares. No fractional shares shall be issued upon conversion of this Note. In lieu
thereof, the Company shall pay to the Holder an amount in cash equal to the product obtained by multiplying the Preferred Stock Conversion Price, the Common Stock Conversion Price, the Series E Conversion Price or the Adjusted Series E Price, as the
case may be, by the fraction of a share not issued upon such conversion. 
 3. Warrant Coverage.  

(a) Issuance of Warrant. The Company shall issue to the Holder (or an affiliate of the Holder designated in writing to the Company),
upon the earliest of (i) the closing of a Qualified Financing, (ii) immediately prior to the consummation of a Corporate Transaction, (iii) the date that the Holder makes a Payment Demand (as defined below), (iv) the date of any
prepayment of the outstanding principal and accrued but unpaid interest under the Note (“Prepayment”) and (v) the Maturity Date, a warrant or warrants substantially in the form attached hereto as Exhibit A
(the “Warrant”) exercisable for the series and number of shares of Preferred Stock or Common Stock as the case may be of the Company as follows: 

(i) If the Company issues the Warrant in connection with the closing of a Qualified Financing that occurs on or before the Maturity
Date, the number of shares of Preferred Stock or Common Stock as the case may be of the Company equal to (a) thirty percent (30%) multiplied by the highest principal balance of this Note, divided by (b) the Preferred Stock Conversion
Price or the Common Stock Conversion Price; or 
 (ii) If the Company issues the Warrant in connection with a Corporate Transaction,
automatic conversion of the Note pursuant to Section 2(c), a Payment Demand or Prepayment, the number of shares of Series E Preferred Stock of the Company equal to (x) thirty percent (30%) multiplied by the highest principal balance
of this Note, divided by (y) the Adjusted Series E Price. 
 (b) Exercise Price. If the Company issues the Warrant in connection
with the closing of a Qualified Financing, the exercise price of the Warrant shall be the Preferred Stock Conversion Price or the Common Stock Conversion Price. If the Company issues the Warrant in connection a Corporation Transaction, automatic
conversion of the Note pursuant to Section 2(c), a Payment Demand or Prepayment, the exercise price of the Warrant shall be the Adjusted Series E Price. 

  
 3. 

 (c) Rights of Underlying Securities. If the Warrant is exercisable for shares of the
Company’s Preferred Stock pursuant to Section 3(a)(i) above, the exercise shares shall have the same rights and obligations, including registration rights, as the Company’s Preferred Stock issued in the Qualified Financing. If the
Warrant is exercisable for shares of the Company’s Series E Preferred Stock pursuant to Section 3(a)(ii) above, the exercise shares shall have the same rights and obligations, including registration rights, as the Company’s Series E
Preferred Stock, as provided in the Fourth Amended and Restated Stockholders Agreement, dated May 14, 2009, as further amended from time to time, and related documents. The Company shall perform, or cause to be performed, all acts, and execute
and deliver all agreements, amendments, instruments and other documents necessary or required to grant the Holder the rights described in this Section 3(c). 

(d) Agreement. The Company and the Holder, having adverse interests and as a result of arm’s length bargaining, agree that: 

(i) The Warrants are not to be issued as compensation; 

(ii) The aggregate fair market value of this Note, if issued apart from the Warrant, is Nine Hundred Ninety Dollars ($990) per One
Thousand Dollars ($1,000) of aggregate face value of the Note, and the aggregate fair market value of the Warrant, if issued apart from the Note, is Ten Dollars ($10) per One Thousand Dollars ($1,000) of aggregate face value of the Notes; and 

(iii) All tax returns and other information return of the Company and the Holder relative to this Note and Warrant issued pursuant
hereto shall consistently reflect the matters agreed to in clauses (i) through (iii) above. 
 4. Default. 

(a) Each of the following events shall be an “Event of Default” hereunder:

 (i) the Company engages in any liquidation, dissolution or winding up of the Company (as contemplated by Article 3,
Section A.4(a) of the Company’s Restated Certificate of Incorporation, dated as of June 14, 2012, as amended from time to time (the “Certificate of Incorporation”); 

(ii) the Company files any petition or action for relief under any bankruptcy, reorganization, insolvency or moratorium law or any
other law for the relief of, or relating to, debtors, now or hereafter in effect, or makes any assignment for the benefit of creditors or takes any corporate action in furtherance of any of the foregoing; 

(iii) an involuntary petition is filed against the Company under any bankruptcy statute now or hereafter in effect, or a custodian,
receiver, trustee, assignee for the benefit of creditors (or other similar official) is appointed to take possession, custody or control of any property of the Company; 

  
 4. 

 (iv) the Company executes an assignment with respect to a majority of its assets; 

(v) the Company breaches, in any material respect, any warranty or agreement made by Company in this Note and, as to any breach that
is capable of cure, Company fails to cure such breach within fifteen (15) days of the Company becoming aware of the occurrence of such breach 

(vi) the Company defaults in any agreement between the Company and a third party that gives the third party the right to accelerate
any Indebtedness exceeding $100,000 upon such default or that could reasonably be expected to cause a material adverse effect on the Company; and 

(vii) a judgment in the aggregate amount of at least $50,000 is rendered against the Company and is unsatisfied or unstayed for ten
(10) days. 
 “Indebtedness” means (i) all indebtedness for borrowed money or the deferred
purchase price of property or services, (ii) all obligations evidenced by notes, bonds, debentures or similar instruments, (iii) all capital lease obligations and (iv) any direct or indirect liability, contingent or otherwise, of the
Company with respect to any indebtedness or other liability or obligation of another person, including, without limitation, any such liability or obligation guaranteed, endorsed or co-made by the Company other than those liabilities, obligation or
endorsements made in the ordinary course of business. 
 (b) Upon the occurrence of any Event of Default hereunder,
(i) all unpaid principal, accrued interest and other amounts owing hereunder shall, at the option of the Holder, and, in the case of an Event of Default pursuant to Section 4(a)(ii) or (iii) above, automatically, be immediately due,
payable and collectible by the Holder pursuant to applicable law and (ii) the Holder may elect at its option to demand payment therefor (the “Payment Demand”). 

(c) Upon the occurrence and during the continuance of any Event of Default, interest shall accrue at the rate of 12% per annum.

 (d) In the event of any Event of Default hereunder, the Company shall pay all reasonable attorneys’ fees and court costs
incurred by the Holder in enforcing and collecting this Note. 
 5. Further Indebtedness. So long as any amounts are owing under this
Note, the Company shall not create, incur or assume any material Indebtedness, other than Indebtedness incurred in the ordinary course of business, without the prior written consent of the Holder; provided that such consent shall not be unreasonably
withheld. 
 6. Miscellaneous. 

(a) Successors and Assigns. The terms and conditions of this Note shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties. Notwithstanding the foregoing, the Company may not assign, by operation of law or otherwise, its rights or obligations under this Note without the prior written consent of the Holder. 

  
 5. 

 (b) Governing Law. This Note shall be governed by and construed under the laws of the
State of Colorado as applied to agreements among Colorado residents, made and to be performed entirely within the State of Colorado. 

(c) Titles and Subtitles. The titles and subtitles used in this Note are used for convenience only and are not to be considered in
construing or interpreting this Note. 
 (d) Notices. All notices required or permitted hereunder shall be in writing and shall be
deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, if not, then on the next business day,
(c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery,
with written verification of receipt. All communications shall be sent to the Company at 1450 Infinite Drive, Louisville, Colorado 80027, and to the Holder at Cooley LLP, 380 Interlocken Crescent, Broomfield, CO 80021, or at such other address as
the Company or the Holder may designate by ten (10) days’ advance written notice to the other parties hereto. 
 (e)
Modification; Waiver. No modification or waiver of any provision of this Note or consent to departure therefrom shall be effective without the written consent of the Company and the Holder and then shall be effective only in the specific
instance and for the specific purpose for which it was given. The right to plead any and all statutes of limitations as a defense to any demands hereunder is hereby waived to the full extent permitted by law. 

(f) Cumulative Remedies. The Holder’s rights and remedies hereunder shall be cumulative. The Holder shall have all other rights
and remedies not inconsistent herewith as provided by law or in equity. No exercise by the Holder of one right or remedy shall be deemed an election, and no waiver by the Holder of any Event of Default shall be deemed a continuing waiver. 

(g) Entire Agreement. This Note and the Exhibit hereto constitute the full and entire understanding and agreement between the parties
with regard to the subjects hereof and no party shall be liable or bound to any other party in any manner by any representations, warranties, covenants and agreements except as specifically set forth herein or therein. 

(h) Independent Counsel. The Company acknowledges that Cooley LLP has not offered legal advice to the Company with regard to this Note
and that the Company has been advised to seek independent counsel review of the provisions contained herein. The Company further acknowledges has been given a reasonable opportunity to seek the advice of independent counsel of its choice with
respect to this Note and the Exhibit and that the Company has availed itself of that opportunity if and to the extent the Company deemed it appropriate to do so. 

[SIGNATURE PAGE FOLLOWS] 

  
 6. 

 
			
	GLOBEIMMUNE, INC.
		
	By:	 	/s/ Timothy C. Rodell
		 	 Timothy C. Rodell, M.D.
 Chief Executive
Officer & President

	
	HOLDER:
	
	COOLEY LLP
		
	By:	 	/s/ Brent D. Fassett
		 	 Brent D. Fassett
 Partner

 EXHIBIT A 

FORM OF WARRANT 

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE
SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 

GLOBEIMMUNE, INC. 

WARRANT TO PURCHASE SERIES [__] PREFERRED STOCK 
  

			
	No. PW-[            ]	  	__________, 200_

 Void After
                                         
                
 THIS
CERTIFIES THAT, for value received, [NAME OF HOLDER], with its principal office at__________________________, or assigns (the
“Holder” or “Purchaser”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from GLOBEIMMUNE, INC., a Delaware
corporation, with its principal office at 1450 Infinite Drive, Louisville, CO 80027 (the “Company”),
[                    ] shares of Series [__] Preferred Stock of the Company (the “Preferred Stock”), as
provided herein. 
 Immediately prior to the closing of the Company’s first firm commitment underwritten public offering of its Common
Stock registered under the Securities Act of 1933, as amended (an “Initial Offering”), this Warrant shall become exercisable for that number of shares of Common Stock of the Company into which the shares of Preferred Stock
issuable under this Warrant would then be convertible, so long as such shares, if this Warrant had been exercised prior to such Initial Offering, would have been converted into shares of the Company’s Common Stock pursuant to the automatic
conversion provisions (or otherwise) of the Company’s Certificate of Incorporation. 
 1. DEFINITIONS. As used
herein, the following terms shall have the following respective meanings: 
 “Exercise Period” shall mean the time
period commencing with the date of this Warrant and ending on the later of (i) ten (10) years following the date hereof and (ii) five (5) years following the closing of the Company’s Initial Offering. 

“Exercise Price” shall mean $[            ] per
share, subject to adjustment pursuant to Section 5 below. 

 “Exercise Shares” shall mean the shares of the Company’s Preferred
Stock issuable upon exercise of this Warrant, subject to adjustment pursuant to the terms herein, including but not limited to adjustment pursuant to Section 5 below. 

2. EXERCISE OF WARRANT. The rights represented by this Warrant may be exercised in whole
or in part at any time during the Exercise Period, by delivery of the following to the Company at its address set forth above (or at such other address as it may designate by notice in writing to the Holder): 

(a) an executed Notice of Exercise in the form attached hereto; 

(b) payment of the Exercise Price either (i) in cash or by check, or (ii) by cancellation of indebtedness; and 

(c) this Warrant. 
 Upon
the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so purchased, registered in the name of the Holder or persons affiliated with the Holder, if the Holder so designates, shall be issued and
delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so exercised. 
 The person in
whose name any certificate or certificates for Exercise Shares are to be issued upon exercise of this Warrant shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the
Exercise Price was made, irrespective of the date of delivery of such certificate or certificates, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed
to have become the holder of such shares at the close of business on the next succeeding date on which the stock transfer books are open. 

2.1 Net Exercise. Notwithstanding any provisions herein to the contrary, if the fair market value of one
share of the Company’s Preferred Stock is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment of cash, the Holder may elect (the “Conversion
Right”) to receive shares equal to the value (as determined below) of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company together with the properly endorsed Notice of
Exercise in which event the Company shall issue to the Holder a number of shares of Preferred Stock computed using the following formula: 
  

							
		 	X = 	 	 Y (A-B)
	 	
		 		 	A	 	

  
 2 

 
					
	Where	  	X =	  	the number of shares of Preferred Stock to be issued to the Holder
			
		  	Y =	  	the number of shares of Preferred Stock purchasable under the Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being canceled (at the date of such calculation)
			
		  	A =	  	the fair market value of one share of the Company’s Preferred Stock (at the date of such calculation)
			
		  	B =	  	Exercise Price (as adjusted to the date of such calculation)

 For purposes of the above calculation, the fair market value of one share of Preferred Stock shall be:

 (a) the product of (i) the average daily Market Price (as defined below) during the period of the most recent 10 days, ending
on the last business day before the effective date of exercise of the Conversion Right, on which the national securities exchanges were open for trading and (ii) the number of shares of the Common Stock (as defined herein) into which each
Exercise Share is convertible on such date; or 
 (b) if no class of Common Stock is then listed or admitted to trading on any
national securities exchange or quoted in the over-counter market, the fair market value of one share of Preferred Stock shall be as determined in good faith by the Board of Directors of the Company, taking into account the most recently or
concurrently completed arm’s-length transaction between the Company and an unaffiliated third party, the closing of which occurs within the six months preceding or on the date of such calculation, if any. 

If the Common Stock is traded on a national securities exchange or admitted to unlisted trading privileges on such an exchange, or is listed
on the Global Market System (the “Global Market System”) of the Nasdaq, the “Market Price” as of a specified day shall be the last reported sale price of Common Stock on such exchange or on the Global
Market System on such date or if no such sale is made on such day, the mean of the closing bid and asked prices for such day on such exchange or on the Global Market System. If the Common Stock is not so listed or admitted to unlisted trading
privileges, the “Market Price” as of a specified day shall be the mean of the last bid and asked prices reported on such date (x) by the Nasdaq or (y) if reports are unavailable under clause (x) above by the
National Quotation Bureau Incorporated. If the Common Stock is not so listed or admitted to unlisted trading privileges and bid and ask prices are not reported, the “Market Price” as of a specified day shall be determined in
good faith by the Board of Directors of the Company. 

  
 3 

 3. COVENANTS OF THE COMPANY.

 3.1. Covenants as to Exercise Shares. The Company covenants and agrees that all Exercise Shares that may be issued upon the
exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants
and agrees that the Company will at all times during the Exercise Period, have authorized and reserved, free from preemptive rights, a sufficient number of shares of its Preferred Stock to provide for the exercise of the rights represented by this
Warrant. If at any time during the Exercise Period the number of authorized but unissued shares of Preferred Stock shall not be sufficient to permit exercise of this Warrant, the Company will take such corporate action as may, in the opinion of its
counsel, be necessary to increase its authorized but unissued shares of Preferred Stock to such number of shares as shall be sufficient for such purposes. 

3.2. No Impairment. Except and to the extent as waived or consented to by the Holder, the Company will not, by amendment of its
Certificate of Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the provisions of this Warrant and in the taking of all such action as may be necessary or appropriate in order to protect
the exercise rights of the Holder against impairment. 
 3.3. Notices of Record Date. In the event of any taking by the Company of a
record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend which is the same as cash dividends paid in previous quarters) or other
distribution, the Company shall mail to the Holder, at least ten (10) days prior to the date specified herein, a notice specifying the date on which any such record is to be taken for the purpose of such dividend or distribution. 

3.4. Notice of Expiration. If this Warrant has not been fully exercised on or before the date thirty (30) days prior to the end of
the Exercise Period, the Company shall thereafter provide Holder with at least twenty (20) days advance written notice of the date on which this Warrant is to expire. If the Company fails to provide such notice, the Exercise Period shall be
extended until the date thirty (30) days after the date said notice is provided to Holder. 
 4. REPRESENTATIONS,
WARRANTIES AND COVENANTS OF HOLDER. 
 4.1. Acquisition of
Warrant for Personal Account. The Holder represents and warrants that it is acquiring the Warrant solely for its account for investment and not with a view to or for sale or distribution of said Warrant or any part thereof, other than potential
transfers between affiliates (including affiliated funds). The Holder also represents that the entire legal and beneficial interests of the Warrant and Exercise Shares the Holder is acquiring is being acquired for, and will be held for, its account
only. 

  
 4 

 4.2. Securities Are Not Registered. 

(a) The Holder understands that the Warrant and the Exercise Shares have not been registered under the Securities Act of 1933, as
amended (the “Act”) on the basis that no distribution or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding its
representations, the Holder has a present intention of acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the
securities. The Holder has no such present intention, other than potential transfers between affiliates (including affiliated funds). 

(b) The Holder recognizes that the Warrant and the Exercise Shares must be held indefinitely unless they are subsequently registered
under the Act or an exemption from such registration is available. 
 (c) The Holder is aware that neither the Warrant nor the
Exercise Shares may be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met, including, among other things, the existence of a public market for the shares, the availability of certain current public information about
the Company, the resale following the required holding period under Rule 144 and the number of shares being sold during any three month period not exceeding specified limitations. Holder is aware that the conditions for resale set forth in Rule 144
have not been satisfied and that the Company presently has no plans to satisfy these conditions in the foreseeable future. 
 4.3.
Disposition of Warrant and Exercise Shares. 
 (a) The Holder further agrees not to make any disposition of all or any part of
the Warrant or Exercise Shares in any event unless and until: 
 (i) The Company shall have received a letter secured by the Holder
from the Securities and Exchange Commission stating that no action will be recommended to the Commission with respect to the proposed disposition; or 

(ii) There is then in effect a registration statement under the Act covering such proposed disposition and such disposition is made in
accordance with said registration statement; or 
 (iii) The Holder shall have notified the Company of the proposed disposition and
shall have furnished the Company with a statement of the circumstances surrounding the proposed disposition; provided, however, that such statement will not be required if the disposition is permitted under Rule 144 of the Securities Act. 

  
 5 

 (b) The Holder agrees not to sell this Warrant or the Exercise Shares during a period
specified by the representative of the underwriters of Common Stock (not to exceed one hundred eighty (180) days) following the effective date of the initial registration statement of the Company filed under the Act, so long as all officers,
directors, and 1% stockholders have executed similar agreements and are similarly restricted from selling the Company’s stock. 

(c) Notwithstanding the provisions of paragraphs (a) and (b) above, the Holder may assign this Warrant and the Exercise
Shares to (i) any partner or retired partner of the Holder if Holder is a partnership, (ii) any member or former member of the Holder if Holder is a limited liability company, (iii) any affiliate, including affiliated funds or
(iv) any family member or trust for the benefit of the Holder if the Holder is an individual; provided that the Company is given written notice thereof. 

(d) The Holder understands and agrees that all certificates evidencing the shares to be issued to the Holder may bear the following
legend: 
 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE
SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 

5. ADJUSTMENT OF EXERCISE PRICE; EFFECT OF
ORGANIC CHANGES 
 5.1. Adjustment of Exercise Price. In the event of changes in the outstanding
Preferred Stock of the Company by reason of stock dividends, splits, recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations, liquidations, or the like, the number and class of shares available under
the Warrant in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the total number, class, and kind of shares as the Holder would have owned
had the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment. The form of this Warrant need not be changed because of any adjustment in the number of Exercise Shares
subject to this Warrant. 

  
 6 

 5.2. Reorganization, Reclassification, Consolidation, Merger or Sale. If any
recapitalization, reclassification or reorganization of the capital stock of the Company, or any consolidation or merger of the Company with another corporation, or the sale of all or substantially all of its assets or other transaction shall be
effected in such a way that holders of the Company’s Preferred Stock shall be entitled to receive stock, securities, or other assets or property (an “Organic Change”), then, as a condition of such Organic Change, lawful
and adequate provisions shall be made by the Company whereby the Holder hereof shall thereafter have the right to purchase and receive (in lieu of the shares of the Preferred Stock of the Company immediately theretofore purchasable and
receivable upon the exercise of the rights represented hereby) such shares of stock, securities or other assets or property as may be issued or payable with respect to or in exchange for a number of outstanding shares of such Preferred Stock equal
to the number of shares of such stock immediately theretofore purchasable and receivable upon the exercise of the rights represented hereby. In the event of any Organic Change, appropriate provision shall be made by the Company with respect to the
rights and interests of the Holder of this Warrant to the end that the provisions hereof (including, without limitation, provisions for adjustments of the Exercise Price and of the number of shares purchasable and receivable upon the exercise of
this Warrant) shall thereafter be applicable, in relation to any shares of stock, securities or assets thereafter deliverable upon the exercise hereof. The Company will not effect any such consolidation, merger or sale unless, prior to the
consummation thereof, the successor corporation (if other than the Company) resulting from such consolidation or the corporation purchasing such assets shall assume by written instrument reasonably satisfactory in form and substance to the
Holders of a majority in interest of the warrants to purchase Preferred Stock then outstanding, executed and mailed or delivered to the registered Holder hereof at the last address of such Holder appearing on the books of the Company, the obligation
to deliver to such Holder such shares of stock, securities or assets as, in accordance with the foregoing provisions, such Holder may be entitled to purchase. 

5.3. Certain Events. If any change in the outstanding Preferred Stock of the Company or any other event occurs as to which the other
provisions of this Section 5 are not strictly applicable or if strictly applicable would not fairly protect the purchase rights of the Holder of the Warrant in accordance with such provisions, then the Board of Directors of the Company shall
make an adjustment in the number and class of shares available under the Warrant, the Exercise Price or the application of such provisions, so as to protect such purchase rights as aforesaid. The adjustment shall be such as to give the Holder of the
Warrant upon exercise for the same aggregate Exercise Price the total number, class and kind of shares as he would have owned had the Warrant been exercised prior to the event and had he continued to hold such shares until after the event requiring
adjustment. 
 6. FRACTIONAL SHARES. No fractional shares shall be issued upon the exercise of this
Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of 

  
 7 

 
determining whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall,
in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then current fair market value of an Exercise Share by such fraction. 

7. NO STOCKHOLDER RIGHTS. This Warrant in and of itself shall not entitle the Holder to
any voting rights or other rights as a stockholder of the Company. 
 8. TRANSFER OF
WARRANT. Subject to applicable laws, this Warrant and all rights hereunder are transferable, by the Holder in person or by duly authorized attorney, upon delivery of this Warrant and the form of assignment attached hereto to any
transferee designated by Holder. 
 9. LOST, STOLEN, MUTILATED OR
DESTROYED WARRANT. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant,
include the surrender thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the
allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone. 
 10. NOTICES,
ETC. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent
during normal business hours of the recipient, if not, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after
deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company at the address listed on the signature page and to Holder at
___________________ or at such other address as the Company or Holder may designate by ten (10) days advance written notice to the other parties hereto. 

11. ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms
and conditions contained herein. 
 12. GOVERNING LAW. This Warrant and all rights, obligations and
liabilities hereunder shall be governed by the laws of the State of Colorado. 

  
 8 

 [Remainder of Page Intentionally Left Blank] 

 

  
 9 

 IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its duly authorized officer as of                     , 2009 

 

			
	GLOBEIMMUNE, INC. 
		
	By:	 	 

 
			
		
	Name:	 	 

 
			
		
	Title:	 	 

 
			
		
	Address:	 	 1450 Infinite Drive
 Louisville, CO
80027

  
 10 

 NOTICE OF EXERCISE 

TO: GLOBEIMMUNE, INC. 

(1)     ̈    The undersigned hereby elects to purchase
________ shares of the Preferred Stock of GLOBEIMMUNE, INC. (the “Company”) pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price
in full, together with all applicable transfer taxes, if any. 
          ̈     The undersigned hereby elects to purchase ________ shares of the Preferred Stock of GLOBEIMMUNE, INC. (the
“Company”) pursuant to the terms of the net exercise provisions set forth in Section 2.1 of the attached Warrant, and shall tender payment of all applicable transfer taxes, if any. 

(2) Please issue a certificate or certificates representing said shares of Preferred Stock in the name of the undersigned or in such other
name as is specified below: 
  
  

(Name) 
  

 
  

 
 (Address) 

(3) The undersigned represents that (i) the aforesaid shares of Preferred Stock are being acquired for the account of the undersigned for
investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares; (ii) the undersigned is aware of the Company’s
business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company; (iii) the undersigned is experienced in making
investments of this type and has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting the undersigned’s own interests; (iv) the
undersigned understands that the shares of Preferred Stock issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption
from the registration provisions of the Securities Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and, because such securities have not been registered under the Securities
Act, they must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available; (v) the undersigned is aware that the aforesaid shares of Preferred Stock may not be sold pursuant
to Rule 144 adopted under the Securities Act unless certain conditions are met and until the undersigned has held the shares for the number of years prescribed by Rule 144, that among the conditions for use of the Rule is the availability of current
information to the public about the Company and the Company has not made such information available and has no present plans to do so; and (vi) the undersigned agrees not to make any disposition of all or any part of the aforesaid shares of
Preferred Stock unless and until there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with said registration statement, or the undersigned has
provided the Company with an opinion of counsel satisfactory to the Company, stating that such registration is not required. 
  

					
			
	  
	 		 	  

	(Date)	 		 	(Signature)
			
	  
	 		 	  

		 		 	(Print name)

  
 1 

 ASSIGNMENT FORM 

(To assign the foregoing Warrant, execute 

this form and supply required information. 

Do not use this form to purchase shares.) 

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby
assigned to 
  

			
		
	Name:	 	 
		 	(Please Print)
		
	Address:	 	 
		 	(Please Print)

 Dated: _________________ 

					
			
	 Holder’s
 Signature:
	 	 	 	
			
	 Holder’s
 Address:
	 	 	 	

  
 NOTE: The signature to this Assignment Form must
correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of
authority to assign the foregoing Warrant.EX-4.7

 Exhibit 4.7 

Warrant No. _____ 
 THIS WARRANT AND THE
SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE
TRANSFERRED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, OR (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY
SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
 Date of Issuance:
___________ 
 GLOBEIMMUNE, INC. 

WARRANT CERTIFICATE 
 FOR
VALUE RECEIVED, GlobeImmune, Inc., a Delaware corporation (the “Company”), hereby certifies that __________, or his, her or its registered transferees, successors or assigns (each person or entity holding all or a part of
this Warrant being referred to as a “Holder”) is the registered holder of this Warrant (the “Warrant”) to purchase the number of Warrant Shares (as defined below) which is equal to (x) $___________ divided by
(y) the Exercise Price (as defined below), as adjusted from time to time as provided herein, during the Exercise Period (as defined below), all subject to the following terms and conditions. 

This Warrant is one in a series of similar warrants (collectively, the “Warrants”) issued pursuant to the offering
(the “Offering”) described in the Private Placement Memorandum, dated January 27, 2014 (as amended and supplemented from time to time and including the annexes thereto, the “Memorandum”), and the related
Subscription Agreements (the “Subscription Agreements”) by and between the Company and the original holders of the Warrants. 

For purposes of this Warrant the following terms shall have the following meanings: 

“Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New
York are authorized or required by law to remain closed. 
 “Common Stock” means the Common Stock, par value $0.001
per share, of the Company. 

  
 1 

 “Determination Date” means the earliest date on which the Exercise Price is
determined as described in the definition of “Exercise Price.” 
 “Equity Securities” means shares of the
Company’s capital stock and any securities convertible into, exercisable or exchangeable for, or otherwise giving the holder thereof the right to subscribe for or otherwise acquire, shares of the Company’s capital stock (with or without
additional consideration), except that such defined term shall not include any award issued by the Company to any employee, director or consultant in such capacity pursuant to the terms of any plan, agreement or other arrangement described in the
Memorandum or any Equity Securities issuable pursuant to such award. 
 “Exercise Price” means (i) the
IPO Exercise Price if an IPO is consummated on or before the First Anniversary, (ii) if no IPO is consummated on or before the First Anniversary and Equity Securities are issued in a Subsequent Round on or before the First Anniversary, the
Subsequent Round Price, or (iii) in the event that neither an IPO nor a Subsequent Round is consummated on or before the First Anniversary, the Qualifying Convertible Preferred Price. 

The Exercise Price shall be determined as follows: 

(a) If an IPO is consummated on or before the First Anniversary, the Exercise Price will be the IPO Exercise Price and no
further determination of the Exercise Price will be required. 
 (b) If no IPO is consummated on or before the First
Anniversary and Equity Securities are issued in a Subsequent Round on or before the First Anniversary, no later than two (2) Business Days following the First Anniversary, the Company shall provide the Placement Agent with a written notice (the
“Subsequent Round Notice”) describing the terms of the Subsequent Round and the Company’s calculation of the Subsequent Round Price in reasonable detail. The Subsequent Round Price set forth in the Subsequent Round Notice shall
become final and binding unless the Placement Agent provides a written notice of objection (a “Subsequent Round Notice of Objection”) to the Company within five (5) Business Days after its receipt of the Subsequent Round
Notice, which Subsequent Round Notice of Objection must specify the basis of the Placement Agent’s objection in reasonable detail. Upon timely receipt of a Subsequent Round Notice of Objection, the Company and the Placement Agent shall
negotiate in good faith for a period not to exceed thirty calendar days after the Placement Agent’s receipt of the Subsequent Round Notice to resolve the Placement Agent’s objection. In the event that, despite the use of good faith
efforts, the Company and the Placement Agent do not agree on the Subsequent Round Price, the determination of the Subsequent Round Price as approved by the Company’s Board of Directors, acting in its good faith business judgment, shall be final
and binding on all parties. 
 (c) In the event that neither an IPO nor a Subsequent Round is consummated on or before the
First Anniversary and the Company has converted the Notes into shares of Qualifying Convertible Preferred Stock pursuant to the terms of the Notes, the Exercise Price shall be the Qualifying Convertible Preferred Price set forth in the terms of the
Qualifying Convertible Preferred Stock and no further determination of the Exercise 

  
 2 

 
Price will be required. If the Company has not previously converted the Notes into shares of Qualifying Preferred Stock effective as of the First Anniversary, no later than five (5) Business
Days after the First Anniversary, the Company shall provide the Placement Agent with a written notice (the “Qualifying Convertible Preferred Stock Notice”) which Qualifying Convertible Preferred Stock Notice shall (i) provide a
calculation in reasonable detail of the Qualifying Convertible Preferred Price (the “Qualifying Convertible Preferred Price Calculation”), and (iii) include a proposed amendment to the Company’s Restated Certificate of
Incorporation, as amended, creating the Qualifying Convertible Preferred Stock and setting forth the relative rights, powers, privileges and limitations of thereof (the “Draft Certificate of Amendment”). The Qualifying Convertible
Preferred Price and the Draft Certificate of Amendment set forth in the Qualifying Convertible Preferred Stock Notice shall become final and binding on the Company and the Holder unless the Placement Agent provides a written notice of objection (a
“Qualifying Convertible Preferred Notice of Objection”) to the Company within five (5) Business Days after its receipt of the Qualifying Convertible Preferred Stock Notice, which Qualifying Convertible Preferred Notice of
Objection shall specify the basis of the Placement Agent’s objection in reasonable detail and, if applicable, include a mark-up of the Draft Certificate of Amendment. Upon timely receipt of a Qualifying Convertible Preferred Notice of
Objection, the Company and the Placement Agent shall negotiate in good faith for a period not to exceed thirty calendar days after the Placement Agent’s receipt of the Qualifying Convertible Preferred Stock Notice to resolve the Placement
Agent’s objection to resolve the Placement Agent’s objection. In the event that, despite the use of their respective good faith efforts, the Company and the Placement Agent do not agree on the Qualifying Convertible Preferred Price and/or
the final terms of the Draft Certificate of Amendment, the determination of the Qualifying Convertible Preferred Price and the terms of the Draft Certificate of Amendment as approved by the Company’s Board of Directors, acting in their good
faith business judgment, shall be final and binding on the Company and the Holder. 
 (d) Not later than two Business Days
after the Determination Date, the Company shall provide written notice to the Holder and the holders of record of the Warrants of the Exercise Price determined as described above which notice shall also advise such holders whether the Warrant Shares
shall be comprised of Common Stock or Preferred Stock. 
 “Expiration Date” means the fifth anniversary of the First
Closing. 
 “First Closing” has the meaning ascribed to such term in the Subscription Agreements. 

 “First Anniversary” means the first anniversary of the First Closing. 

“IPO” means an initial underwritten public offering of Common Stock. 

“IPO Exercise Price” means the per share price at which the Common Stock is first offered to the public in an IPO. 

  
 3 

 “Preferred Stock” means the Preferred Stock, par value $0.001 per share, of the
Company. 
 “Qualifying Convertible Preferred Stock” means a newly created series of convertible preferred stock of the
Company, which Qualifying Convertible Preferred Stock shall be pari passu as to dividends and upon liquidation on an proportionate basis with, and have all other rights and privileges as, the most senior class or series of the Company’s
preferred stock then outstanding; provided, however, that such Qualifying Preferred Stock shall have “full-ratchet” antidilution rights and an original issue price equal to the quotient obtained by dividing (i) $45,000,000, by
(ii) the aggregate number of outstanding shares of Common Stock on the First Anniversary (assuming, solely for the purpose of determined the aggregate number of shares of Common Stock deemed to be outstanding on the First Anniversary, the full
conversion, exercise or exchange of all securities outstanding on the First Anniversary convertible into, exercisable or exchangeable for, or otherwise giving the holder thereof the right to subscribe for or otherwise acquire, shares of Common Stock
(with or without additional consideration), other than the Notes). 
 “Qualifying Convertible Preferred Price” means the
original issue price of the Qualifying Convertible Preferred Stock as set forth in the Company’s Restated Certificate of Incorporation, as amended to create the Qualifying Convertible Preferred Stock. 

“Sale of the Company” means either: (a) a transaction or series of related transactions in which a person, or a group of
related persons, acquires from stockholders of the Company shares representing more than fifty percent (50%) of the outstanding voting power of the Company; or (b) a transaction that qualifies as an Event of Sale as such term is defined in
the Company’s Restated Certificate of Incorporation, as amended or restated from time to time. 
 “Stockholders
Agreement” means that certain Fifth Amended and Restated Stockholders Agreement, dated as of January 14, 2010, by and among the Company and the parties identified on Schedule 1 and Schedule 2 thereto, as amended or restated from time
to time. 
 “Subsequent Round” means the issuance and sale by the Company of Equity Securities at any time after the First
Closing in one or more arms-length equity financings resulting in gross proceeds to the Company of at least $3.0 million, provided, that if the Company consummates more than one Subsequent Round, “Subsequent Round” shall mean the first
Subsequent Round consummated by the Company. 
 “Subsequent Round Price” means the highest cash per share price paid or
deemed to be paid by the investors in a Subsequent Round for the Equity Securities issued in the Subsequent Round. 
 “Warrant
Shares” shall mean either: (i) shares of Common Stock if an IPO is consummated on or before the First Anniversary; (ii) if an IPO is not consummated on or before the First Anniversary and Equity Securities are issued in a
Subsequent Round on or before the First Anniversary, shares of such Equity Securities; or (iii) in the event that neither an IPO nor a Subsequent Round is consummated on or before the First Anniversary, shares of Qualifying Convertible
Preferred Stock. 

  
 4 

	1.	DURATION AND EXERCISE OF WARRANTS 

 (a) Exercise Period. The Holder may exercise this
Warrant in whole or in part at any time from and after the Determination Date and on or before 5:00 P.M., New York Time, on the earlier of (i) the Expiration Date or (ii) the Early Termination Date (as defined below), at which time this
Warrant shall become void and of no value (the “Exercise Period”). 
 (b) Exercise Procedures. 

(i) While this Warrant remains outstanding and exercisable in accordance with Section 1(a), in addition to the manner set forth in
Section 1(b)(ii) below, the Holder may exercise this Warrant in whole or in part at any time and from time to time by: 
 (A) delivery
to the Secretary of the Company of a duly executed copy of the Notice of Exercise attached as Exhibit A; 
 (B) surrender of
this Warrant to the Secretary of the Company at its principal offices or at such other office or agency as the Company may specify in writing to the Holder; and 

(C) payment of the then-applicable Exercise Price per share multiplied by the number of Warrant Shares being purchased upon exercise of the
Warrant (such amount, as calculated at the time of each exercise, the “Aggregate Exercise Price”) made in the form of cash, or by certified check, bank draft or money order payable in lawful money of the United States of America or
in the form of a Cashless Exercise to the extent permitted in Section 1(b)(ii) below. 
 (ii) In addition to the provisions of
Section 1(b)(i) above, if at any time while this Warrant is exercisable a registration statement covering the resale of the Warrant Shares by the Holder is not effective with the Securities and Exchange Commission (the “SEC”)
and the fair value of one Warrant Share is greater than the Exercise Price (at the date of calculation set forth below), the Holder may, in its sole discretion, exercise all or any part of the Warrant in a “cashless” or
“net-issue” exercise (a “Cashless Exercise”) by delivering to the Company (A) the Notice of Exercise and (B) the original Warrant, pursuant to which the Holder shall surrender the right to receive upon exercise
of this Warrant a number of Warrant Shares having a value (as determined below) equal to the Aggregate Exercise Price in which case, the Company shall issue to the Holder the number of Warrant Shares calculated using the following formula: 

 

							
		 	X = 	 	 Y * (A - B)
	 	
		 		 	A	 	

  

					
	with:	  	X =	  	the number of Warrant Shares to be issued to the Holder
			
		  	Y =	  	the number of Warrant Shares with respect to which the Warrant is being exercised
			
		  	A =	  	the fair value of one Warrant Share on the date of exercise of this Warrant
			
		  	B =	  	the then-current Exercise Price of the Warrant

  
 5 

 For purposes of the above calculation, the “fair value” of a Warrant Share as of
any date shall be the result obtained by multiplying (x) the number of shares of Common Stock into which each Warrant Share is ultimately convertible, exercisable or exchangeable, by the Market Value of one share of the Common Stock as of such
date. “Market Value” means, as of any date, (a) if the Common Stock is then listed or quoted on the New York Stock Exchange, the NYSE MKT, the NASDAQ Global Select Market, the NASDAQ Global Market or the NASDAQ Capital Market
or any other national securities exchange, the closing price per share of the Common Stock for such date (or the nearest preceding date) on the primary eligible market or exchange on which the Common Stock is then listed or quoted; (b) if
clause (a) is not applicable and prices for the Common Stock are then quoted on the OTC Bulletin Board or any tier of the OTC Markets, the closing bid price per share of the Common Stock for such date (or the nearest preceding date) so quoted;
(c) if clauses (a) and (b) are not applicable and prices for the Common Stock are then reported in the “Pink Sheets” published by the National Quotation Bureau Incorporated (or a similar organization or agency succeeding to
its functions of reporting prices), the most recent closing bid price per share of the Common Stock so reported; or (d) if the Common Stock is not publicly traded as set forth above, the fair market value per share of Common Stock last
determined by the Board of Directors of the Company for purposes of complying with the requirements of Section 409A of the Internal Revenue Code. So long as clause (d) is applicable, the Company shall upon request advise the Holder in
writing of the most recently determined fair market value of the Common Stock for Section 409A purposes. 
 For purposes of Rule 144
promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in a cashless exercise transaction shall be deemed to have been acquired by the Holder, and the holding period for such shares shall be
deemed to have commenced, on the date this Warrant was originally issued. 
 (iii) Upon the exercise of this Warrant in compliance with the
provisions of this Section 1(b), the Company shall promptly issue and cause to be delivered to the Holder a certificate for the Warrant Shares purchased by the Holder. Each exercise of this Warrant shall be effective immediately prior to the
close of business on the date (the “Date of Exercise”) that the conditions set forth in Section 1(b) have been satisfied, as the case may be. On the first Business Day following the date on which the Company has received each
of the Notice of Exercise and the Aggregate Exercise Price (or notice of a Cashless Exercise in accordance with Section 1(b)(ii)) (the “Exercise Delivery Documents”), the Company shall transmit an acknowledgment of receipt of
the Exercise Delivery Documents to the Company’s transfer agent, if other than the Company (the “Transfer Agent”). On or before the third Business Day following the date on which the Company has received all of the Exercise
Delivery Documents (the “Share Delivery Date”), the Company shall (X) provided that the Transfer Agent is participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program, upon
the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with DTC through its Deposit Withdrawal Agent
Commission system, or (Y) if 

  
 6 

 
the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program or if the Warrant Shares are not eligible for inclusion therein, issue and dispatch by overnight
courier to the address as specified in the Notice of Exercise, a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to
such exercise. Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of
the date of delivery of the certificates evidencing such Warrant Shares. 
 (c) Partial Exercise. This Warrant shall be exercisable,
either in its entirety or, from time to time in part, only for the number of Warrant Shares available for exercise under this Warrant. If this Warrant is exercised and the number of Warrant Shares represented by this Warrant submitted for exercise
is greater than the actual number of Warrant Shares being acquired upon such an exercise, then the Company shall, as soon as practicable and in no event later than five (5) Business Days after any such exercise and at its own expense, issue a
new Warrant of like tenor representing the right to purchase the remaining number of Warrant Shares purchasable hereunder after such exercise. 

(d) Disputes. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant
Shares, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance with Section 16. 

(e) Stockholders Agreement. The Holder hereby agrees that, as a condition to exercise of this Warrant for shares of Equity Securities
issued in a Subsequent Round or for shares of Qualifying Convertible Preferred Stock, the Holder, if not already a party to the Stockholders Agreement, will execute and deliver a counterpart signature page to the Stockholders Agreement and become an
“Investor” party thereunder. 
  

	2.	ISSUANCE OF WARRANT SHARES 

 (a) The Company covenants that all Warrant Shares will, upon
issuance in accordance with the terms of this Warrant, be (i) duly authorized, fully paid and non-assessable, and (ii) free from all liens, charges and security interests, with the exception of claims arising through the acts or omissions
of any Holder and except as arising from applicable Federal and state securities laws. 
 (b) The Company shall register this Warrant upon
records to be maintained by the Company for that purpose in the name of the record holder of such Warrant from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner thereof for the purpose of any
exercise thereof, any distribution to the Holder thereof and for all other purposes. 
 (c) The Company will not, by amendment of its
certificate of incorporation, by-laws or through any reorganization, transfer of assets, consolidation, merger, dissolution, issuance or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of
the terms to be observed or performed hereunder by the Company, and will take all actions consistent with the carrying out of all the provisions of this Warrant. 

  
 7 

	3.	ADJUSTMENTS OF EXERCISE PRICE, NUMBER AND TYPE OF WARRANT SHARES 

 (a) The Exercise Price and
the Warrant Shares issuable upon the exercise of this Warrant shall be subject to adjustment from time to time upon the occurrence of certain events described in this Section 3. 

(i) Subdivision or Combination of Stock. In case the Company shall at any time after the First Closing and prior to the Expiration Date
subdivide (whether by way of stock dividend (other than as a result of an event provided for in Section 3(a)(ii) below), stock split or otherwise) its outstanding Warrant Shares into a greater number of shares, the Exercise Price in effect
immediately prior to such subdivision shall be proportionately reduced and the number of Warrant Shares shall be proportionately increased, and conversely, in case the outstanding Warrant Shares shall be combined (whether by way of stock
combination, reverse stock split or otherwise) into a smaller number of shares, the Exercise Price in effect immediately prior to such combination shall be proportionately increased and the number of Warrant Shares issuable upon the exercise of this
Warrant shall be proportionately decreased. The Exercise Price and the Warrant Shares issuable upon the exercise of this Warrant, as so adjusted, shall be readjusted in the same manner upon the happening of any successive event or events described
in this Section 3(a)(i). 
 (ii) Dividends in Stock, Property, Reclassification. If at any time, or from time to time, after the
First Closing and prior to the Expiration Date, (x) there are changes in the outstanding Warrant Shares by reason of recapitalization, reclassification or reorganization of the capital stock of the Company (other than as a result of any event
provided for in Section 3(a)(i) above), or (y) all of the holders of Warrant Shares shall have received or become entitled to receive, without payment therefore (other than as a result of any event provided for in Section 3(a)(i)
above): 
 (A) any shares of stock or other securities that are at any time directly or indirectly convertible into or exchangeable for
Warrant Shares, or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution, or 

(B) additional stock or other securities or property (including cash) by way of spin-off, split-up, reclassification, combination of shares
or similar corporate rearrangement, 
 then and in each such case, the Exercise Price and the number of Warrant Shares issuable upon exercise of this
Warrant shall be adjusted proportionately, and the Holder hereof shall, upon the exercise of this Warrant, be entitled to receive, in addition to the number of shares of Warrant Shares receivable upon exercise of this Warrant, and without payment of
any additional consideration therefor, the amount of stock and other securities and property (including cash in the cases referred to above) that such Holder would hold on the date of such exercise had such

  
 8 

 
Holder been the holder of record of such Warrant Shares as of the date on which such holders of Warrant Shares received or became entitled to receive such shares or all other additional stock and
other securities and property; provided, however, that such adjustment shall not be made with respect to, and this Warrant shall terminate if not exercised prior to, the events set forth in Section 4 below. The Exercise Price and the
Warrant Shares issuable upon the exercise of this Warrant, as so adjusted, shall be readjusted in the same manner upon the happening of any successive event or events described in this Section 3(a)(ii). 

(b) Certificate as to Adjustments. Upon the occurrence of each adjustment or readjustment pursuant to this Section 3, the Company
at its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each Holder of this Warrant a certificate setting forth such adjustment or readjustment and showing in detail the facts upon
which such adjustment or readjustment is based. 
 4.        EARLY TERMINATION. The Company shall provide to the
Holder at least twenty (20) days advance written notice of any Sale of the Company and this Warrant shall terminate unless exercised immediately prior to the consummation of such Sale of the Company (the date of such termination, the
“Early Termination Date”). 
  

	5.	TRANSFERS AND EXCHANGES OF WARRANT AND WARRANT SHARES 

 (a) Registration of Transfers and
Exchanges. Subject to Section 5(c) and 5(d), upon the Holder’s surrender of this Warrant, with a duly executed copy of the Form of Assignment attached as Exhibit B, to the Secretary of the Company at its principal offices or at
such other office or agency as the Company may specify in writing to the Holder, the Company shall register in the Company’s books and records the transfer of all or any portion of this Warrant. Upon such registration of transfer, the Company
shall issue a new Warrant, in substantially the form of this Warrant, evidencing the acquisition rights transferred to the transferee and a new Warrant, in similar form, evidencing the remaining acquisition rights not transferred, to the Holder
requesting the transfer. 
 (b) Warrant Exchangeable for Different Denominations. The Holder may exchange this Warrant for a new
Warrant or Warrants, in substantially the form of this Warrant, evidencing in the aggregate the right to purchase the number of Warrant Shares which may then be purchased hereunder, each of such new Warrants to be dated the date of such exchange and
to represent the right to purchase such number of Warrant Shares as shall be designated by the Holder. The Holder shall surrender this Warrant with duly executed instructions regarding such re-certification of this Warrant to the Secretary of the
Company at its principal offices or at such other office or agency as the Company may specify in writing to the Holder. 
 (c)
Restrictions on Transfers. This Warrant may not be transferred at any time unless such transfer is (i) registered under the Securities Act, (ii) made in accordance with the requirements of Rule 144 of the Securities Act or
(iii) exempt from registration under the Securities Act as evidenced by a written opinion of legal counsel addressed to the Company that the proposed transfer of the Warrant may be effected without registration under the Securities Act, which
opinion will be in form and from counsel reasonably satisfactory to the Company. 

  
 9 

 (d) Permitted Transfers and Assignments. Notwithstanding any provision to the contrary in
this Section 5, the Holder may transfer, with or without consideration, this Warrant or any of the Warrant Shares (or a portion thereof) to the Holder’s Affiliates (as such term is defined under Rule 144 of the Securities Act) without
obtaining the opinion from counsel that may be required by Section 5(c)(iii), provided, that the Holder delivers to the Company and its counsel certification, documentation, and other assurances reasonably required by the Company’s
counsel to enable the Company’s counsel to render an opinion to the Company’s Transfer Agent that such transfer does not violate applicable securities laws. 
  

	6.	MUTILATED OR MISSING WARRANT CERTIFICATE 

 If this Warrant is mutilated, lost, stolen or
destroyed, upon request by the Holder, the Company will, at its expense, issue, in exchange for and upon cancellation of the mutilated Warrant, or in substitution for the lost, stolen or destroyed Warrant, a new Warrant, in substantially the form of
this Warrant, representing the right to acquire the equivalent number of Warrant Shares; provided, that, the Holder provides the Company with an affidavit of loss and an indemnity agreement reasonably satisfactory to the Company. 

 

	7.	PAYMENT OF TAXES 

 The Company will pay all transfer and stock issuance taxes attributable to
the preparation, issuance and delivery of this Warrant and the Warrant Shares (and replacement Warrants) including, without limitation, all documentary and stamp taxes; provided, however, that the Company shall not be required to pay
any tax in respect of the transfer of this Warrant, or the issuance or delivery of certificates for Warrant Shares or other securities in respect of the Warrant Shares to any person or entity other than to the Holder. 

 

	8.	FRACTIONAL WARRANT SHARES 

 No fractional Warrant Shares shall be issued upon exercise of this
Warrant. The Company, in lieu of issuing any fractional Warrant Share, shall round up the number of Warrant Shares issuable to nearest whole share. 
  

	9.	NO STOCK RIGHTS AND LEGEND 

 No holder of this Warrant, as such, shall be entitled to vote or
be deemed the holder of the Warrant Shares or any other securities of the Company that may at any time be issuable on the exercise hereof, nor shall anything contained herein be construed to confer upon the holder of this Warrant, as such, the
rights of a stockholder of the Company or the right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or give or withhold consent to any corporate action or to receive notice of meetings or
other actions affecting stockholders (except as provided herein), or to receive dividends or subscription rights or otherwise (except as provide herein). 

Each certificate for Warrant Shares initially issued upon the exercise of this Warrant, and each certificate for Warrant Shares issued to any
subsequent transferee of any such certificate, shall be stamped or otherwise imprinted with a legend in substantially the following form: 

  
 10 

 “THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT OF 1933,
AS AMENDED, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, OR (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933,
AS AMENDED.” 
  

	10.	RESERVED. 

  

	11.	NOTICES 

 Any notice or other communication required or permitted to be given hereunder shall
be in writing and shall be deemed effectively given: (a) upon personal delivery to the party notified, (b) when sent by confirmed email or facsimile if sent during normal business hours of the recipient, if not, then on the next Business
Day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the Company at the address, email or facsimile number provided in the Subscription Agreement executed in connection herewith, and to the Holder at the address, email or facsimile number
provided in the Subscription Agreement for such Holder executed in connection herewith, or to such other address as the Company or the Holder shall have furnished in writing in accordance with the provisions of this Section 11. 

 

	12.	SEVERABILITY 

 If a court of competent jurisdiction holds any provision of this Warrant invalid
or unenforceable, the other provisions of this Warrant will remain in full force and effect. Any provision of this Warrant held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or
unenforceable. 
  

	13.	BINDING EFFECT 

 This Warrant shall be binding upon and inure to the sole and exclusive benefit
of the Company, its successors and assigns, the registered Holder or Holders from time to time of this Warrant and the Warrant Shares. 
  

	14.	SURVIVAL OF RIGHTS AND DUTIES 

 This Warrant shall terminate and be of no further force and
effect on the earlier of the expiration of the Exercise Period or the date on which this Warrant has been exercised in full. 
  

	15.	GOVERNING LAW 

 This Warrant will be governed by and construed under the laws of the State of
New York without regard to conflicts of laws principles that would require the application of any other law. 

  
 11 

	16.	DISPUTE RESOLUTION 

 Except as otherwise provided herein, in the case of a dispute as to the
determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile within two (2) Business Days of receipt of the Notice of
Exercise giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three (3) Business Days of such
disputed determination or arithmetic calculation being submitted to the Holder, then the Company shall, within two (2) Business Days, submit via confirmed email or facsimile (a) the disputed determination of the Exercise Price to an
independent, reputable investment bank selected by the Company and approved by the Holder or (b) the disputed arithmetic calculation of the Warrant Shares to the Company’s independent, outside accountant. The Company shall cause at its
expense the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than ten (10) Business Days from the time it receives the disputed
determinations or calculations. Such investment bank’s or accountant’s determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error. 

 

	17.	NOTICES OF RECORD DATE 

 Upon (a) any establishment by the Company of a record date of the
holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend or other distribution, or right or option to acquire securities of the Company, or any other right, or (b) any
capital reorganization, reclassification, recapitalization, merger or consolidation of the Company with or into any other corporation, any transfer of all or substantially all the assets of the Company, or any voluntary or involuntary dissolution,
liquidation or winding up of the Company, or the sale, in a single transaction, of a majority of the Company’s voting stock (whether newly issued, or from treasury, or previously issued and then outstanding, or any combination thereof), the
Company shall mail to the Holder at least ten (10) Business Days, or such longer period as may be required by law, prior to the record date specified therein, a notice specifying (i) the date established as the record date for the purpose
of such dividend, distribution, option or right and a description of such dividend, option or right, (ii) the date on which any such reorganization, reclassification, transfer, consolidation, merger, dissolution, liquidation or winding up, or
sale is expected to become effective and (iii) the date, if any, fixed as to when the holders of record of Warrant Shares shall be entitled to exchange their Warrant Shares for securities or other property deliverable upon such reorganization,
reclassification, transfer, consolation, merger, dissolution, liquidation or winding up. 
  

	18.	RESERVATION OF SHARES 

 Prior to the expiration of the Exercise Period, the Company shall
reserve and keep available out of its authorized but unissued capital stock for issuance upon the exercise of this Warrant, free from pre-emptive rights, such number of Warrant Shares for which this Warrant shall from time to time be exercisable.
The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation. Without limiting the generality of the foregoing,

  
 12 

 
the Company covenants that it will use its best efforts to take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and
nonassessable Warrant Shares upon the exercise of this Warrant and use its best efforts to obtain all such authorizations, exemptions or consents, including but not limited to consents from the Company’s stockholders or Board of Directors or
any public regulatory body, as may be necessary to enable the Company to perform its obligations under this Warrant. 
  

	19.	NO THIRD PARTY RIGHTS 

 This Warrant is not intended, and will not be construed, to create any
rights in any parties other than the Company and the Holder, and no person or entity may assert any rights as third-party beneficiary hereunder. 
  

	20.	AMENDMENT PROVISION 

 Any term of this Warrant may be amended, supplemented or waived
upon the written consent of the Company and the holders of a majority in interest of all outstanding Warrants, and such amendment, supplement or waiver shall be binding upon the Company and all holders of the Warrants, including the Holder, whether
or not the Holder has consented to such amendment, supplement or waiver; provided, however, that (a) any such amendment, supplement or waiver must apply to all outstanding Warrants, and (b) the Expiration Date, the determination of
the number of Warrant Shares subject to this Warrant or of the Exercise Price of such Warrant Shares, and the right to exercise this Warrant may not be altered or waived, without the written consent of the Holder. 

[SIGNATURE PAGE FOLLOWS] 

  
 13 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed as of the date first
set forth above. 
  

					
	GLOBEIMMUNE, INC.
		
	By:	 	/s/ Timothy C. Rodell
		 	Name:	 	Timothy C. Rodell
		 	Title:	 	Chief Executive Officer

  
 14 

 EXHIBIT A 

NOTICE OF EXERCISE 
 (To be
executed by the Holder of Warrant if such Holder desires to exercise Warrant) 
 To GlobeImmune, Inc.: 

The undersigned hereby irrevocably elects to exercise this Warrant and to purchase thereunder, ___________________ Warrant Shares issuable
upon exercise of the Warrant and delivery of: 
 (1) $_________ (in cash as provided for in the foregoing Warrant) and any applicable taxes
payable by the undersigned pursuant to such Warrant; and 
 (2) __________ Warrant Shares (pursuant to a Cashless Exercise in accordance
with Section 1(b)(ii) of the Warrant) (check here if the undersigned desires to deliver an unspecified number of shares equal the number sufficient to effect a Cashless Exercise
[            ]). 
 The undersigned requests that certificates for such
shares be issued in the name of: 
  

	
	
	   

 (Please print name, address and social security or federal employer 

identification number (if applicable)) 

	
	
	   

	
	   

 If the shares issuable upon this exercise of the Warrant are not all of the Warrant Shares which the Holder is
entitled to acquire upon the exercise of the Warrant, the undersigned requests that a new Warrant evidencing the rights not so exercised be issued in the name of and delivered to: 

 

	
	
	   

 (Please print name, address and social security or federal employer 

identification number (if applicable)) 

	
	
	   

	
	   

 The undersigned hereby represents and warrants that (i) the undersigned meets the requirements of at
least one of the suitability standards for an “accredited investor” as that term is defined in Regulation D as promulgated by the United States Securities and Exchange Commission; (ii) the undersigned is acquiring the Warrant Shares
solely for the undersigned’s account for investment purposes only and not with a view to or intent of resale or distribution thereof, in whole or in part, in violation of the Securities Act of 1933, as amended (the “Act”), and the
undersigned has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the Act, without prejudice, however, to the undersigned’s right at all times to sell or otherwise dispose of all
or any part of the Warrant Shares in compliance with applicable federal and state securities laws and in compliance with any transfer restriction to which the applicable Warrant Shares may be subject at any time or from time to

  
 15 

 
time; and (iii) the undersigned has such knowledge and experience in financial, tax, and business matters, and, in particular, investments in securities, so as to enable it to utilize the
information made available to it in connection with the Offering to evaluate the merits and risks of an investment in the Company and the Warrant Shares and to make an informed investment decision with respect thereto. 

 

			
		
	Name of Holder (print):	 	 

 
			
		
	(Signature):	 	 

 
			
		
	(By:)	 	 

 
			
		
	(Title:)	 	 

 
			
		
	Dated:	 	 

  
 16 

 EXHIBIT B 

FORM OF ASSIGNMENT 
 FOR VALUE
RECEIVED, ___________________________________ hereby sells, assigns and transfers to each assignee set forth below all of the rights of the undersigned under the Warrant (as defined in and evidenced by the attached Warrant) to acquire the number of
Warrant Shares set opposite the name of such assignee below and in and to the foregoing Warrant with respect to said acquisition rights and the shares issuable upon exercise of the Warrant: 

 

									
	 Name of Assignee
	  	 	  	 Address
	  	 	  	 Number of Shares

		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	

 If the total of the Warrant Shares are not all of the Warrant Shares evidenced by the foregoing Warrant, the
undersigned requests that a new Warrant evidencing the right to acquire the Warrant Shares not so assigned be issued in the name of and delivered to the undersigned. 

 

			
		
	Name of Holder (print):	 	 

 
			
		
	(Signature):	 	 

 
			
		
	(By:)	 	 

 
			
		
	(Title:)	 	 

 
			
		
	Dated:	 	 

 Schedule of Warrantholders to Form of Warrant Certificate 

 

									
	Warrant No.	  	Date of Issuance	  	 Name of

Warrantholder
	  	Dollar Amount
for Warrant
Share Equation	 
	1	  	January 31, 2014	  	Bobcat Property Trust of Angel Fire, New Mexico	  	 	$350,000.00	  
	2	  	January 31, 2014	  	Precedo Fund L.P	  	 	$250,000.00	  
	3	  	January 31, 2014	  	ACP X, LP	  	 	$500,000.00	  
	4	  	January 31, 2014	  	Christopher Travelle	  	 	$100,000.00	  
	5	  	January 31, 2014	  	Robert L. Montgomery	  	 	$25,000.00	  
	6	  	January 31, 2014	  	Shaun Jacob Trust Dated October 8, 2013	  	 	$50,000.00	  
	7	  	January 31, 2014	  	Joel Kovacs	  	 	$15,000.00	  
	8	  	January 31, 2014	  	Laura Pogoda Dell	  	 	$150,000.00	  
	9	  	January 31, 2014	  	Haitham Elsheikh	  	 	$150,000.00	  
	10	  	January 31, 2014	  	Fred A. Wagner Jr. and Allison K. Wagner, Community Property	  	 	$25,000.00	  
	11	  	January 31, 2014	  	Matthew D. and Regina M. MacLean, Community Property	  	 	$25,000.00	  
	12	  	January 31, 2014	  	Emanuel Haghighat	  	 	$10,000.00	  
	13	  	January 31, 2014	  	Warrenton Ventures LLC	  	 	$50,000.00	  
	14	  	January 31, 2014	  	D&R Partners, LLC	  	 	$100,000.00	  
	15	  	January 31, 2014	  	Richard M. Spitalny	  	 	$25,000.00	  
	16	  	January 31, 2014	  	James Lawler & Sarah Dunn Lawler	  	 	$30,000.00	  
	17	  	January 31, 2014	  	Allan Rothstein	  	 	$50,000.00	  
	18	  	January 31, 2014	  	Doug Cohen	  	 	$50,000.00	  
	19	  	January 31, 2014	  	Lester Petracca	  	 	$500,000.00	  
	20	  	January 31, 2014	  	Webster Powell PC PSP	  	 	$50,000.00	  
	21	  	January 31, 2014	  	New Century Holdings, LLLP	  	 	$100,000.00	  
	22	  	February 11, 2014	  	SJO Worldwide LLC	  	 	$250,000.00	  
	23	  	February 11, 2014	  	David Blonder	  	 	$150,000.00	  
	24	  	February 11, 2014	  	Vekoe Partners LLC	  	 	$100,000.00	  
	25	  	February 11, 2014	  	Robyn Schreiber	  	 	$60,000.00	  
	26	  	February 11, 2014	  	Abba Properties Partnership	  	 	$100,000.00	  
	27	  	February 11, 2014	  	James Menz & Susan Menz	  	 	$25,000.00	  
	28	  	February 11, 2014	  	BM LLP	  	 	$50,000.00	  

									
	29	  	February 11, 2014	  	Archon Securities DB Pension Plan	  	 	$50,000.00	  
	30	  	February 11, 2014	  	James F. Holmes	  	 	$25,000.00	  
	31	  	February 11, 2014	  	Peter Sabo	  	 	$50,000.00	  
	32	  	February 11, 2014	  	Edward M. Dunn	  	 	$250,000.00	  
	33	  	February 11, 2014	  	B. Ted Kosir Living Trust	  	 	$62,500.00	  
	34	  	February 11, 2014	  	Margerie Kramer	  	 	$25,000.00	  
	35	  	February 11, 2014	  	Dorith Schwartz	  	 	$25,000.00	  
	36	  	February 11, 2014	  	Veramarie Garvey	  	 	$25,000.00	  
	37	  	February 11, 2014	  	William N. Strawbridge	  	 	$25,000.00	  
	38	  	February 11, 2014	  	Michael Ellerson and Diane Ellerson JTWROS	  	 	$20,000.00	  
	39	  	February 11, 2014	  	David Schellhardt	  	 	$250,000.00	  
	40	  	February 11, 2014	  	Michael Zimmerman	  	 	$25,000.00	  
	41	  	February 11, 2014	  	Rexford Capital LLC	  	 	$250,000.00	  
	42	  	February 11, 2014	  	GP Trust	  	 	$50,000.00	  
	43	  	February 11, 2014	  	Andre Bourque	  	 	$25,000.00	  
	44	  	February 11, 2014	  	Robert H. Rowley & Dorothy W. Rowley Trust	  	 	$20,000.00	  
	45	  	February 11, 2014	  	Bruce A. Ferguson & Dawn E. Gunter, TIC	  	 	$30,000.00	  
	46	  	February 11, 2014	  	Prouty Family Revocable Trust	  	 	$20,000.00	  
	47	  	February 11, 2014	  	A. Lauren Rhude Trust	  	 	$20,000.00	  
	48	  	February 11, 2014	  	Howard Weiss and Ruth Weiss	  	 	$50,000.00	  
	49	  	February 11, 2014	  	RBC Cap. Markets LLC Cust. Adam Stern IRA	  	 	$200,000.00	  
	50	  	February 11, 2014	  	Ali Bijan Rafie Trust	  	 	$30,000.00	  
	51	  	February 11, 2014	  	JKW Family Ltd.	  	 	$150,000.00	  
	52	  	February 11, 2014	  	DB Investor Group LLC	  	 	$50,000.00	  
	53	  	February 11, 2014	  	Matheous Alexandrou & Charles Socrates	  	 	$75,000.00	  
	54	  	February 11, 2014	  	Deborah Chin	  	 	$25,000.00	  
	55	  	February 11, 2014	  	Robert Consley	  	 	$100,000.00	  
	56	  	February 11, 2014	  	Michael F. Hannley & Ruth Hannley	  	 	$20,000.00	  
	57	  	February 11, 2014	  	Peter W. Janssen	  	 	$25,000.00	  
	58	  	February 11, 2014	  	Benjamin & Jamie Kohnen	  	 	$25,000.00	  

									
	59	  	February 11, 2014	  	Vantage FBO Michael D. MacLean IRA	  	 	$25,000.00	  
	60	  	February 11, 2014	  	Veronica Marano & Thomas M. Volckening	  	 	$100,000.00	  
	61	  	February 11, 2014	  	Jacob Movtady	  	 	$10,000.00	  
	62	  	February 11, 2014	  	Harvey Schilowitz DDS Defined Benefit Pension Fund	  	 	$25,000.00	  
	63	  	February 11, 2014	  	Vantage FBO Derek Sroufe Roth IRA	  	 	$100,000.00	  
	64	  	February 11, 2014	  	Dennis Wong	  	 	$100,000.00	  
	65	  	February 11, 2014	  	Brian Behrens	  	 	$25,000.00	  
	66	  	February 11, 2014	  	John Burgraff	  	 	$75,000.00	  
	67	  	February 11, 2014	  	David M. Kutz & Patricia A. Kutz JTWROS	  	 	$100,000.00	  
	68	  	February 11, 2014	  	Vantage FBO Laurence E. Lof, Roth IRA	  	 	$100,000.00	  
	69	  	February 11, 2014	  	Nickel River, LLC	  	 	$100,000.00	  
	70	  	February 11, 2014	  	Stan Alex Miroshnik	  	 	$100,000.00	  
	71	  	February 11, 2014	  	Keith Murphy	  	 	$200,000.00	  
	72	  	February 11, 2014	  	Gary Miles & Alverta Miles JT	  	 	$25,000.00	  
	73	  	February 11, 2014	  	Aaron Lehman	  	 	$25,000.00	  
	74	  	February 11, 2014	  	Four Jr Investments Ltd.	  	 	$100,000.00	  
	75	  	February 11, 2014	  	Balsam Capital Management	  	 	$25,000.00	  
	76	  	February 11, 2014	  	Joseph Schump	  	 	$25,000.00	  
	77	  	February 11, 2014	  	Mat 9 LLC	  	 	$100,000.00	  
	78	  	February 11, 2014	  	Evan Myrianthopoulos	  	 	$25,000.00	  
	79	  	February 11, 2014	  	Vasili & Elisabeth Myrianthopoulos JTWROS	  	 	$25,000.00	  
	80	  	February 11, 2014	  	NSH 2008 Family Trust	  	 	$25,000.00	  
	81	  	February 11, 2014	  	Chad R. Bundy	  	 	$25,000.00	  
	82	  	February 11, 2014	  	Stourbridge Investments LLC	  	 	$25,000.00	  
	83	  	February 11, 2014	  	GJG Life Sciences, LLC	  	 	$275,000.00	  
	84	  	February 11, 2014	  	Millennium MSO, Inc.	  	 	$25,000.00	  
	85	  	February 11, 2014	  	Robert L. Kwint	  	 	$22,500.00	  
	86	  	February 11, 2014	  	Michael J. Garnick	  	 	$250,000.00	  
	87	  	February 11, 2014	  	Washington Research Foundation	  	 	$20,000.00	  

									
	88	  	February 11, 2014	  	Ian Stern	  	 	$10,000.00	  
	89	  	February 11, 2014	  	Lorne & Vivian Kramer	  	 	$25,000.00	  
	90	  	February 11, 2014	  	E. Michael Pompizzi	  	 	$25,000.00	  
	91	  	February 11, 2014	  	Collier Holdings LLC	  	 	$25,000.00	  
		  		  		  	  
	  
	 
	Total Principal Amount:	  		  	 	$7,500,000.00

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]